PARIS, June 23 — Antibody therapies are offering promising treatment breakthroughs for cancer and other illnesses, generating greater investor interest more than 20 years after they were first commercialised.
The treatment, Enhertu, was already authorised for breast cancer patients who had large amounts of a protein called HER2. “We hadn’t seen such progress, in terms of survival, with a chemotherapy treatment for dozens of years,” said Jacot, a professor at the Montpellier Cancer Institute in southern France.
French biotech firm Inatherys is in the first stage of clinical trials of an antibody treatment for leukaemia, its boss Pierre Launay said.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: